Anticipate Debate About Aducanumab for Alzheimer's Disease

You'll hear controversy about aducanumab (Aduhelm), the first new med for Alzheimer's disease in almost 20 years.

It's different than other Alzheimer's meds (donepezil, etc).

Aducanumab is a monoclonal antibody given as an IV infusion every 4 weeks...and it's intended to target and affect the underlying disease.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals